Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.52 |
| ▸ | CHUK | O15111 | 11/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987803 | 0.88 | IKBKB (0.43) | IKBKBCHUKMAPK1HTTUCHL1 | |
| SCHEMBL3415505 | 0.78 | MAPK1 (0.69) | IKBKBCHUKMAPK1HTTKDM1A | |
| SCHEMBL2986429 | 0.73 | L3MBTL1 (0.45) | IKBKBCHUKMAPK1KMT2AKDM4E | |
| SCHEMBL2991150 | 0.71 | APEX1 (0.40) | HTTKDM4EMAPT | |
| SCHEMBL2977630 | 0.70 | KDM4E (0.52) | MAPK1HTTUSP30HSD17B10KDM4E | |
| SCHEMBL3417814 | 0.70 | KMT2A (0.63) | IKBKBCHUKMAPK1HTTKDM1A | |
| SCHEMBL3418171 | 0.70 | KMT2A (0.63) | IKBKBCHUKMAPK1HTTKDM1A | |
| SCHEMBL3411208 | 0.70 | KMT2A (0.63) | IKBKBCHUKMAPK1HTTKDM1A | |
| SCHEMBL2994739 | 0.70 | IKBKB (0.51) | IKBKBCHUKMAPK1KMT2AKDM4E | |
| SCHEMBL2985529 | 0.69 | ALDH1A1 (0.72) | IKBKBCHUKKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | IKBKB 11/4885CHUK 22/4885MAPK1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.